Why the study?
Does maternal treatment with naproxen cause adverse cardiovascular and systemic effects in preterm infants?
Does maternal treatment with naproxen cause adverse cardiovascular and systemic effects in preterm infants?
Maternal treatment with naproxen to delay parturition may cause severe adverse effects in preterm infants, including pulmonary hypertension and death, due to prostaglandin synthesis inhibition.
Maternal naproxen near preterm delivery warrants caution; case report leaves open causality and generalizability.
Twins and a singleton were born at 30 weeks' gestation although naproxen (d-2 (6' methoxy-2-naphthyl) propionic acid) had been given to the mothers in an attempt to delay parturition. Inhibition of prostaglandin synthesis was shown by very low plasma concentrations of prostaglandin E and the ductus arteriosus remained closed despite signs of pulmonary hypertension with severe hypoxaemia. Abnormalities in blood clotting, renal function, and bilirubin metabolism were also found and one infant died. Further studies of the benefits and risks of the inhibition of prostaglandin synthesis are required before this treatment of preterm labour is accepted.
No takes yet. Share an insight, caveat, or question.
Wilkinson et al. (1980) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: